Traws Pharma, Inc. (TRAW) 10-Year Financial Performance & Capital Metrics

TRAW • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutTraws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Show more

Revenue $226K
EBITDA -$49M -143.3%
Net Income -$55M -188.5%
EPS (Diluted) -35.21 -56.0%
Gross Margin 94.69% -5.3%
EBITDA Margin -21830.09% -143.3%
Operating Margin -21835.4% -143.1%
Net Margin -24192.04% -188.5%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Sales declining 36.5% over 5 years
✗Shares diluted 84.9% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-11.87%

5Y-36.47%

3Y0%

TTM554.65%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM36.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.82%

ROCE

10Y Avg-286.31%

5Y Avg-151.82%

3Y Avg-168.77%

Latest-367.01%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.46M	5.55M	787K	1.23M	2.18M	231K	226K	226K	226K	226K
Revenue Growth %	13.32%	-0.52%	-0.86%	0.56%	0.78%	-0.89%	-0.02%	0%	0%	0%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	12K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.05%
Gross Profit+	0	0	0	0	2.18M	231K	226K	226K	226K	214K
Gross Margin %	-	-	-	-	1%	1%	1%	1%	1%	0.95%
Gross Profit Growth %	-	-	-	-	-	-0.89%	-0.02%	0%	0%	-0.05%
Operating Expenses+	35.28M	29.15M	26.44M	24.45M	23.88M	25.22M	16.72M	19.85M	20.52M	49.56M
OpEx % of Revenue	3.08%	5.26%	33.59%	19.91%	10.94%	109.19%	73.99%	87.85%	90.81%	219.3%
Selling, General & Admin	9.38M	9.08M	7.41M	7.59M	8.35M	8.33M	9.43M	8.45M	9.09M	12.29M
SG&A % of Revenue	0.82%	1.64%	9.41%	6.18%	3.82%	36.04%	41.7%	37.38%	40.24%	54.38%
Research & Development	25.89M	20.07M	19.03M	16.87M	15.54M	16.9M	7.3M	11.41M	11.43M	130.31M
R&D % of Revenue	2.26%	3.62%	24.18%	13.74%	7.12%	73.15%	32.29%	50.47%	50.58%	576.6%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-93.04M
Operating Income+	-23.97M	-23.7M	-25.74M	-23.28M	-21.7M	-24.99M	-16.5M	-19.63M	-20.3M	-49.35M
Operating Margin %	-2.09%	-4.27%	-32.7%	-18.96%	-9.94%	-108.19%	-72.99%	-86.85%	-89.81%	-218.35%
Operating Income Growth %	0.62%	0.01%	-0.09%	0.1%	0.07%	-0.15%	0.34%	-0.19%	-0.03%	-1.43%
EBITDA+	-23.82M	-23.61M	-25.65M	-23.23M	-21.68M	-24.98M	-16.48M	-19.61M	-20.28M	-49.34M
EBITDA Margin %	-2.08%	-4.26%	-32.59%	-18.91%	-9.93%	-108.14%	-72.93%	-86.78%	-89.74%	-218.3%
EBITDA Growth %	0.62%	0.01%	-0.09%	0.09%	0.07%	-0.15%	0.34%	-0.19%	-0.03%	-1.43%
D&A (Non-Cash Add-back)	150K	96K	88K	55K	14K	13K	14K	14K	16K	12K
EBIT	-24.01M	-19.65M	-24.08M	-20.53M	-21.7M	-24.99M	-16.5M	-19.63M	-20.3M	-166.52M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-35K	4.05M	1.66M	2.75M	206K	-160K	333K	663K	1.35M	-117.17M
Pretax Income+	-24.01M	-19.65M	-24.08M	-20.53M	-21.49M	-25.15M	-16.16M	-18.96M	-18.95M	-166.52M
Pretax Margin %	-2.1%	-3.54%	-30.6%	-16.72%	-9.85%	-108.89%	-71.52%	-83.91%	-83.84%	-736.83%
Income Tax+	16K	14K	13K	-124K	10K	4K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	0.33%
Net Income+	-23.98M	-19.67M	-24.09M	-20.57M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-54.67M
Net Margin %	-2.09%	-3.55%	-30.61%	-16.75%	-9.85%	-108.9%	-71.52%	-83.91%	-83.84%	-241.92%
Net Income Growth %	0.62%	0.18%	-0.22%	0.15%	-0.05%	-0.17%	0.36%	-0.17%	0%	-1.89%
Net Income (Continuing)	-24.02M	-19.67M	-24.09M	-20.41M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-166.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	830K	830K	830K	0	0	0	0	0	0	0
EPS (Diluted)+	-59062.00	-24975.00	-15056.00	-1870.69	-560.58	-54.21	-24.01	-22.68	-22.57	-35.21
EPS Growth %	0.64%	0.58%	0.4%	0.88%	0.7%	0.9%	0.56%	0.06%	0%	-0.56%
EPS (Basic)	-59062.00	-24975.00	-15056.00	-1870.69	-560.58	-54.21	-24.01	-22.68	-22.57	-35.21
Diluted Shares Outstanding	404	787	1.6K	11K	38.36K	464.1K	673.29K	836.33K	839.55K	1.55M
Basic Shares Outstanding	404	787	1.6K	11K	38.36K	464.1K	673.29K	836.33K	839.55K	1.55M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.18M	23.07M	4.9M	17.77M	23.47M	19.78M	55.43M	39.35M	22.66M	24.95M
Cash & Short-Term Investments	19.8M	21.45M	4.02M	16.97M	22.73M	19.02M	55.07M	38.76M	20.82M	21.34M
Cash Only	19.8M	21.45M	4.02M	16.97M	22.73M	19.02M	55.07M	38.76M	20.82M	21.34M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.5M	31K	59K	35K	98K	37K	28K	29K	18K	1.76M
Days Sales Outstanding	47.92	2.04	27.36	10.4	16.39	58.46	45.22	46.84	29.07	2.85K
Inventory	0	0	0	0	0	542K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	245K	73K	77K	68K	140K	-362K	35K	40K	401K	178K
Total Non-Current Assets+	260K	164K	76K	158K	200K	202K	48K	25K	23K	11K
Property, Plant & Equipment	248K	152K	64K	9K	50K	52K	38K	24K	22K	10K
Fixed Asset Turnover	46.19x	36.49x	12.30x	136.44x	43.66x	4.44x	5.95x	9.42x	10.27x	22.60x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	12K	12K	12K	149K	150K	150K	10K	1K	1K	1K
Total Assets+	23.45M	23.23M	4.98M	17.92M	23.67M	19.99M	55.48M	39.37M	22.68M	24.96M
Asset Turnover	0.49x	0.24x	0.16x	0.07x	0.09x	0.01x	0.00x	0.01x	0.01x	0.01x
Asset Growth %	-0.5%	-0.01%	-0.79%	2.6%	0.32%	-0.16%	1.78%	-0.29%	-0.42%	0.1%
Total Current Liabilities+	7.61M	10.16M	9.98M	8.44M	8.29M	10.02M	6.12M	8.05M	9.22M	11.53M
Accounts Payable	3.42M	5.32M	6.19M	4.04M	4.27M	4.83M	2.76M	3.86M	5.62M	8.19M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	248.99K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	455K	455K	455K	226K	226K	226K	226K	226K	226K	226K
Other Current Liabilities	444K	2.81M	1.26M	2.52M	2.26M	2.72M	1.92M	1.19M	2.37M	265K
Current Ratio	3.05x	2.27x	0.49x	2.11x	2.83x	1.97x	9.06x	4.89x	2.46x	2.16x
Quick Ratio	3.05x	2.27x	0.49x	2.11x	2.83x	1.92x	9.06x	4.89x	2.46x	2.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	7.95M	5.86M	4.1M	3.81M	3.79M	3.24M	3.02M	2.79M	45.06M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	3.4M	1.77M	176K	113K	321K	0	0	0	42.49M
Total Liabilities	12.61M	18.11M	15.84M	12.54M	12.1M	13.81M	9.36M	11.06M	12.01M	56.59M
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-19.8M	-21.45M	-4.02M	-16.97M	-22.73M	-19.02M	-55.07M	-38.76M	-20.82M	-21.34M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	10.84M	5.13M	-10.86M	5.39M	11.57M	6.17M	46.12M	28.31M	10.67M	-31.63M
Equity Growth %	-0.54%	-0.53%	-3.12%	1.5%	1.15%	-0.47%	6.47%	-0.39%	-0.62%	-3.96%
Book Value per Share	26814.27	6514.96	-6788.13	489.86	301.74	13.31	68.50	33.85	12.71	-20.37
Total Shareholders' Equity	10.01M	4.3M	-11.69M	5.39M	11.57M	6.17M	46.12M	28.31M	10.67M	-31.63M
Common Stock	25K	68K	8K	57K	1.11M	124K	209K	209K	210K	36K
Retained Earnings	-318.56M	-338.22M	-362.32M	-381.9M	-403.4M	-428.56M	-444.72M	-463.68M	-482.63M	-649.15M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-22K	-31K	3K	-12K	-18K	14K	-14K	-33K	-23K	-42K
Minority Interest	830K	830K	830K	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-31.24M	-15.81M	-23.82M	-22.7M	-20.83M	-23.07M	-19.49M	-16.29M	-17.93M	-29.79M
Operating CF Margin %	-2.73%	-2.85%	-30.27%	-18.48%	-9.54%	-99.89%	-86.23%	-72.1%	-79.35%	-131.82%
Operating CF Growth %	0.46%	0.49%	-0.51%	0.05%	0.08%	-0.11%	0.16%	0.16%	-0.1%	-0.66%
Net Income	-24.02M	-19.67M	-24.09M	-20.57M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-166.52M
Depreciation & Amortization	150K	96K	88K	55K	14K	13K	14K	14K	16K	12K
Stock-Based Compensation	3.79M	0	0	0	0	369K	576K	1.17M	1.3M	1.39M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	22K	-3.24M	-577K	429K	985K	208K	-321K	0	0	141.9M
Working Capital Changes	-11.17M	3.82M	102K	-1.07M	-327K	1.49M	-3.59M	1.48M	-301K	-6.57M
Change in Receivables	-1.37M	1.47M	-28K	24K	-63K	61K	9K	-1K	11K	-1.75M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-606K	1.9M	863K	-1.45M	232K	562K	-2.08M	1.1M	1.76M	646K
Cash from Investing+	0	0	0	0	-55K	-15K	0	0	-14K	-3.65M
Capital Expenditures	0	0	0	0	-55K	-15K	0	0	-14K	0
CapEx % of Revenue	-	-	-	-	0.03%	0.06%	-	-	0.06%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	7.46M	17.42M	6.36M	35.66M	26.65M	19.36M	55.56M	0	0	33.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	3K	0	589K	4.89M	10.29M	519K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.24M	-15.81M	-23.82M	-22.7M	-20.89M	-23.09M	-19.49M	-16.29M	-17.95M	-29.79M
FCF Margin %	-2.73%	-2.85%	-30.27%	-18.48%	-9.57%	-99.96%	-86.23%	-72.1%	-79.41%	-131.82%
FCF Growth %	0.46%	0.49%	-0.51%	0.05%	0.08%	-0.11%	0.16%	0.16%	-0.1%	-0.66%
FCF per Share	-77271.59	-20093.83	-14887.50	-2063.84	-544.50	-49.75	-28.94	-19.48	-21.38	-19.19
FCF Conversion (FCF/Net Income)	1.30x	0.80x	0.99x	1.10x	0.97x	0.92x	1.21x	0.86x	0.95x	0.54x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-139.16%	-246.35%	-	-381.9%	-253.56%	-283.48%	-61.81%	-50.96%	-97.22%	-
Gross Margin	-	-	-	-	100%	100%	100%	100%	100%	94.69%
Net Margin	-209.31%	-354.62%	-3061.25%	-1675.33%	-985.02%	-10890.48%	-7151.77%	-8391.15%	-8384.07%	-24192.04%
FCF Conversion	1.30x	0.80x	0.99x	1.10x	0.97x	0.92x	1.21x	0.86x	0.95x	0.54x
Revenue Growth	1332%	-51.59%	-85.81%	56.04%	77.77%	-89.42%	-2.16%	0%	0%	0%

Frequently Asked Questions

Growth & Financials

Traws Pharma, Inc. (TRAW) reported $3.0M in revenue for fiscal year 2024. This represents a 99% increase from $1.5M in 2011.

Traws Pharma, Inc. (TRAW) grew revenue by 0.0% over the past year. Growth has been modest.

Traws Pharma, Inc. (TRAW) reported a net loss of $23.0M for fiscal year 2024.

Dividend & Returns

Traws Pharma, Inc. (TRAW) had negative free cash flow of $50.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Traws Pharma, Inc. (TRAW) 10-Year Financial Performance & Capital Metrics

TRAW • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $226K
EBITDA -$49M -143.3%
Net Income -$55M -188.5%
EPS (Diluted) -35.21 -56.0%
Gross Margin 94.69% -5.3%
EBITDA Margin -21830.09% -143.3%
Operating Margin -21835.4% -143.1%
Net Margin -24192.04% -188.5%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Sales declining 36.5% over 5 years
✗Shares diluted 84.9% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-11.87%

5Y-36.47%

3Y0%

TTM554.65%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM36.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM42.82%

ROCE

10Y Avg-286.31%

5Y Avg-151.82%

3Y Avg-168.77%

Latest-367.01%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.46M	5.55M	787K	1.23M	2.18M	231K	226K	226K	226K	226K
Revenue Growth %	13.32%	-0.52%	-0.86%	0.56%	0.78%	-0.89%	-0.02%	0%	0%	0%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	12K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	0.05%
Gross Profit+	0	0	0	0	2.18M	231K	226K	226K	226K	214K
Gross Margin %	-	-	-	-	1%	1%	1%	1%	1%	0.95%
Gross Profit Growth %	-	-	-	-	-	-0.89%	-0.02%	0%	0%	-0.05%
Operating Expenses+	35.28M	29.15M	26.44M	24.45M	23.88M	25.22M	16.72M	19.85M	20.52M	49.56M
OpEx % of Revenue	3.08%	5.26%	33.59%	19.91%	10.94%	109.19%	73.99%	87.85%	90.81%	219.3%
Selling, General & Admin	9.38M	9.08M	7.41M	7.59M	8.35M	8.33M	9.43M	8.45M	9.09M	12.29M
SG&A % of Revenue	0.82%	1.64%	9.41%	6.18%	3.82%	36.04%	41.7%	37.38%	40.24%	54.38%
Research & Development	25.89M	20.07M	19.03M	16.87M	15.54M	16.9M	7.3M	11.41M	11.43M	130.31M
R&D % of Revenue	2.26%	3.62%	24.18%	13.74%	7.12%	73.15%	32.29%	50.47%	50.58%	576.6%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-93.04M
Operating Income+	-23.97M	-23.7M	-25.74M	-23.28M	-21.7M	-24.99M	-16.5M	-19.63M	-20.3M	-49.35M
Operating Margin %	-2.09%	-4.27%	-32.7%	-18.96%	-9.94%	-108.19%	-72.99%	-86.85%	-89.81%	-218.35%
Operating Income Growth %	0.62%	0.01%	-0.09%	0.1%	0.07%	-0.15%	0.34%	-0.19%	-0.03%	-1.43%
EBITDA+	-23.82M	-23.61M	-25.65M	-23.23M	-21.68M	-24.98M	-16.48M	-19.61M	-20.28M	-49.34M
EBITDA Margin %	-2.08%	-4.26%	-32.59%	-18.91%	-9.93%	-108.14%	-72.93%	-86.78%	-89.74%	-218.3%
EBITDA Growth %	0.62%	0.01%	-0.09%	0.09%	0.07%	-0.15%	0.34%	-0.19%	-0.03%	-1.43%
D&A (Non-Cash Add-back)	150K	96K	88K	55K	14K	13K	14K	14K	16K	12K
EBIT	-24.01M	-19.65M	-24.08M	-20.53M	-21.7M	-24.99M	-16.5M	-19.63M	-20.3M	-166.52M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-35K	4.05M	1.66M	2.75M	206K	-160K	333K	663K	1.35M	-117.17M
Pretax Income+	-24.01M	-19.65M	-24.08M	-20.53M	-21.49M	-25.15M	-16.16M	-18.96M	-18.95M	-166.52M
Pretax Margin %	-2.1%	-3.54%	-30.6%	-16.72%	-9.85%	-108.89%	-71.52%	-83.91%	-83.84%	-736.83%
Income Tax+	16K	14K	13K	-124K	10K	4K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	0.33%
Net Income+	-23.98M	-19.67M	-24.09M	-20.57M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-54.67M
Net Margin %	-2.09%	-3.55%	-30.61%	-16.75%	-9.85%	-108.9%	-71.52%	-83.91%	-83.84%	-241.92%
Net Income Growth %	0.62%	0.18%	-0.22%	0.15%	-0.05%	-0.17%	0.36%	-0.17%	0%	-1.89%
Net Income (Continuing)	-24.02M	-19.67M	-24.09M	-20.41M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-166.52M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	830K	830K	830K	0	0	0	0	0	0	0
EPS (Diluted)+	-59062.00	-24975.00	-15056.00	-1870.69	-560.58	-54.21	-24.01	-22.68	-22.57	-35.21
EPS Growth %	0.64%	0.58%	0.4%	0.88%	0.7%	0.9%	0.56%	0.06%	0%	-0.56%
EPS (Basic)	-59062.00	-24975.00	-15056.00	-1870.69	-560.58	-54.21	-24.01	-22.68	-22.57	-35.21
Diluted Shares Outstanding	404	787	1.6K	11K	38.36K	464.1K	673.29K	836.33K	839.55K	1.55M
Basic Shares Outstanding	404	787	1.6K	11K	38.36K	464.1K	673.29K	836.33K	839.55K	1.55M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	23.18M	23.07M	4.9M	17.77M	23.47M	19.78M	55.43M	39.35M	22.66M	24.95M
Cash & Short-Term Investments	19.8M	21.45M	4.02M	16.97M	22.73M	19.02M	55.07M	38.76M	20.82M	21.34M
Cash Only	19.8M	21.45M	4.02M	16.97M	22.73M	19.02M	55.07M	38.76M	20.82M	21.34M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.5M	31K	59K	35K	98K	37K	28K	29K	18K	1.76M
Days Sales Outstanding	47.92	2.04	27.36	10.4	16.39	58.46	45.22	46.84	29.07	2.85K
Inventory	0	0	0	0	0	542K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	245K	73K	77K	68K	140K	-362K	35K	40K	401K	178K
Total Non-Current Assets+	260K	164K	76K	158K	200K	202K	48K	25K	23K	11K
Property, Plant & Equipment	248K	152K	64K	9K	50K	52K	38K	24K	22K	10K
Fixed Asset Turnover	46.19x	36.49x	12.30x	136.44x	43.66x	4.44x	5.95x	9.42x	10.27x	22.60x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	12K	12K	12K	149K	150K	150K	10K	1K	1K	1K
Total Assets+	23.45M	23.23M	4.98M	17.92M	23.67M	19.99M	55.48M	39.37M	22.68M	24.96M
Asset Turnover	0.49x	0.24x	0.16x	0.07x	0.09x	0.01x	0.00x	0.01x	0.01x	0.01x
Asset Growth %	-0.5%	-0.01%	-0.79%	2.6%	0.32%	-0.16%	1.78%	-0.29%	-0.42%	0.1%
Total Current Liabilities+	7.61M	10.16M	9.98M	8.44M	8.29M	10.02M	6.12M	8.05M	9.22M	11.53M
Accounts Payable	3.42M	5.32M	6.19M	4.04M	4.27M	4.83M	2.76M	3.86M	5.62M	8.19M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	248.99K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	455K	455K	455K	226K	226K	226K	226K	226K	226K	226K
Other Current Liabilities	444K	2.81M	1.26M	2.52M	2.26M	2.72M	1.92M	1.19M	2.37M	265K
Current Ratio	3.05x	2.27x	0.49x	2.11x	2.83x	1.97x	9.06x	4.89x	2.46x	2.16x
Quick Ratio	3.05x	2.27x	0.49x	2.11x	2.83x	1.92x	9.06x	4.89x	2.46x	2.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	7.95M	5.86M	4.1M	3.81M	3.79M	3.24M	3.02M	2.79M	45.06M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	3.4M	1.77M	176K	113K	321K	0	0	0	42.49M
Total Liabilities	12.61M	18.11M	15.84M	12.54M	12.1M	13.81M	9.36M	11.06M	12.01M	56.59M
Total Debt+	0	0	0	0	0	0	0	0	0	0
Net Debt	-19.8M	-21.45M	-4.02M	-16.97M	-22.73M	-19.02M	-55.07M	-38.76M	-20.82M	-21.34M
Debt / Equity	-	-	-	-	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	10.84M	5.13M	-10.86M	5.39M	11.57M	6.17M	46.12M	28.31M	10.67M	-31.63M
Equity Growth %	-0.54%	-0.53%	-3.12%	1.5%	1.15%	-0.47%	6.47%	-0.39%	-0.62%	-3.96%
Book Value per Share	26814.27	6514.96	-6788.13	489.86	301.74	13.31	68.50	33.85	12.71	-20.37
Total Shareholders' Equity	10.01M	4.3M	-11.69M	5.39M	11.57M	6.17M	46.12M	28.31M	10.67M	-31.63M
Common Stock	25K	68K	8K	57K	1.11M	124K	209K	209K	210K	36K
Retained Earnings	-318.56M	-338.22M	-362.32M	-381.9M	-403.4M	-428.56M	-444.72M	-463.68M	-482.63M	-649.15M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-22K	-31K	3K	-12K	-18K	14K	-14K	-33K	-23K	-42K
Minority Interest	830K	830K	830K	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-31.24M	-15.81M	-23.82M	-22.7M	-20.83M	-23.07M	-19.49M	-16.29M	-17.93M	-29.79M
Operating CF Margin %	-2.73%	-2.85%	-30.27%	-18.48%	-9.54%	-99.89%	-86.23%	-72.1%	-79.35%	-131.82%
Operating CF Growth %	0.46%	0.49%	-0.51%	0.05%	0.08%	-0.11%	0.16%	0.16%	-0.1%	-0.66%
Net Income	-24.02M	-19.67M	-24.09M	-20.57M	-21.5M	-25.16M	-16.16M	-18.96M	-18.95M	-166.52M
Depreciation & Amortization	150K	96K	88K	55K	14K	13K	14K	14K	16K	12K
Stock-Based Compensation	3.79M	0	0	0	0	369K	576K	1.17M	1.3M	1.39M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	22K	-3.24M	-577K	429K	985K	208K	-321K	0	0	141.9M
Working Capital Changes	-11.17M	3.82M	102K	-1.07M	-327K	1.49M	-3.59M	1.48M	-301K	-6.57M
Change in Receivables	-1.37M	1.47M	-28K	24K	-63K	61K	9K	-1K	11K	-1.75M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-606K	1.9M	863K	-1.45M	232K	562K	-2.08M	1.1M	1.76M	646K
Cash from Investing+	0	0	0	0	-55K	-15K	0	0	-14K	-3.65M
Capital Expenditures	0	0	0	0	-55K	-15K	0	0	-14K	0
CapEx % of Revenue	-	-	-	-	0.03%	0.06%	-	-	0.06%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	7.46M	17.42M	6.36M	35.66M	26.65M	19.36M	55.56M	0	0	33.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	3K	0	589K	4.89M	10.29M	519K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.24M	-15.81M	-23.82M	-22.7M	-20.89M	-23.09M	-19.49M	-16.29M	-17.95M	-29.79M
FCF Margin %	-2.73%	-2.85%	-30.27%	-18.48%	-9.57%	-99.96%	-86.23%	-72.1%	-79.41%	-131.82%
FCF Growth %	0.46%	0.49%	-0.51%	0.05%	0.08%	-0.11%	0.16%	0.16%	-0.1%	-0.66%
FCF per Share	-77271.59	-20093.83	-14887.50	-2063.84	-544.50	-49.75	-28.94	-19.48	-21.38	-19.19
FCF Conversion (FCF/Net Income)	1.30x	0.80x	0.99x	1.10x	0.97x	0.92x	1.21x	0.86x	0.95x	0.54x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-139.16%	-246.35%	-	-381.9%	-253.56%	-283.48%	-61.81%	-50.96%	-97.22%	-
Gross Margin	-	-	-	-	100%	100%	100%	100%	100%	94.69%
Net Margin	-209.31%	-354.62%	-3061.25%	-1675.33%	-985.02%	-10890.48%	-7151.77%	-8391.15%	-8384.07%	-24192.04%
FCF Conversion	1.30x	0.80x	0.99x	1.10x	0.97x	0.92x	1.21x	0.86x	0.95x	0.54x
Revenue Growth	1332%	-51.59%	-85.81%	56.04%	77.77%	-89.42%	-2.16%	0%	0%	0%

Frequently Asked Questions

Growth & Financials

Traws Pharma, Inc. (TRAW) reported $3.0M in revenue for fiscal year 2024. This represents a 99% increase from $1.5M in 2011.

Traws Pharma, Inc. (TRAW) grew revenue by 0.0% over the past year. Growth has been modest.

Traws Pharma, Inc. (TRAW) reported a net loss of $23.0M for fiscal year 2024.

Dividend & Returns

Traws Pharma, Inc. (TRAW) had negative free cash flow of $50.7M in fiscal year 2024, likely due to heavy capital investments.